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Background: EY-6 is one of the newly synthesized indole-
dione derivatives to induce tumor cell-specific cell death. In 
this study, we investigated the mechanism of immunological 
death induced by EY-6 at mouse colon cancer cell as well as 
at the normal immune cell represented by dendritic cell. 
Methods: C57BL/6 mouse syngeneic colon cancer cell 
MC38 was treated with EY-6, and analyzed by MTT for via-
bility test, flow cytometry for confirming surface expressing 
molecules and ELISA for detection of cytokine secretion. 
Normal myeloid-dendritic cell (DC) was ex vivo cultured from 
bone marrow hematopoietic stem cells of C57BL/6 mice 
with GM-CSF and IL-4 to analyze the DC uptake of dead tu-
mor cells and to observe the effect of EY-6 on the normal 
DC. Results: EY-6 killed the MC38 tumor cells in a dose de-
pendent manner (25, 50 and 100μM) with carleticulin induc-
tion. And EY-6 induced the secretion of IFN-γ but not of 
TNF-α from the MC38 tumor cells. EY-6 did not kill the 
ex-vivo cultured DCs at the dose killing tumor cells and did 
slightly but not significantly induced the DC maturation. The 
OVA-specific cross-presentation ability of DC was not in-
duced by chemical treatment (both MHC II and MHC I-re-
stricted antigen presentation). Conclusion: Data indicate 
that the EY-6 induced tumor cell specific and immunological 
cell death by modulation of tumor cell phenotype and cyto-
kine secretion favoring induction of specific immunity elimi-
nating tumor cells.
[Immune Network 2011;11(6):383-389]
INTRODUCTION
The toxicity to the normal cell is the biggest limitation of an-
ti-tumor  therapy  modules  including  chemotherapy  and  ra-
diotherapy. Also as a systemic disease, tumor can’t be treated 
or protected from metastasis by surgery which removes the 
local burden. To achieve the complete elimination of disease, 
one  should  consider  the  systemic  minimal  residual  tumors 
(1). Thus, inducing specific immunity to remove the tumor 
is considered as the promising choice of therapy (2). Recent 
reports address the immunological aspects of certain chemo-
therapeutics (3-6). Generally chemotherapeutics kill the rapid 
proliferating cells including tumor cells as well as bone mar-
row stem cells which are the cause of immune-suppression 
in treated patients. High dose cyclophosphamide, a chemo-
therapeutics, inhibits T cell function and anthracyclines affect 
the macrophages (7-10). On the other hand, low dose cyclo-
phosphamide induces the immunity. Unlike other anthracy-
clines,  doxorubicin  (10)  did  not  inhibit  but  induce  macro-
phage-related anti-tumor activity in vivo. Limited number of 
recent paper reports the immunological death of tumor cells 
killed by certain type of chemotherapeutics. Surface expres-
sion of carleticulin (CRT) or heat-shock proteins on the killed 
tumor cells leads to the induction of tumor-specific immune 
responses (1,11-13). Especially, translocation of cytosolic CRT 
onto the dead tumor cell surface makes the cell more attrac-
tive for uptake by antigen-presenting cell, DC. These findings 
allow us to make the hypothesis that a chemical inducing tu-
mor cell specific and immunological killing may increases the Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell
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tumor-specific immunity thus be a safe and effective anti-tu-
mor  agent.
    The compound EY-6 is the newly synthesized indoledione 
derivatives with transposition of heterocylic ring (QIDs). Early 
study of related QIDs reveals that the compounds induce the 
tumor cell apoptosis by cell cycle control, angiogenesis con-
trol or topoisomerase II inhibition (14-17). In this study, the 
induction  of  immunological  death  of  colon  cancer  cells  by 
EY-6 is observed to learn the scientific basis to develop the 
candidate materials for efficacious and safe anti-cancer drug.
MATERIALS AND METHODS
Animals
Specific  pathogen-free  female  C57BL/6  mice  (H2k
b),  5∼6 
weeks old, were purchased from the Dae-Han BioLink (Eum-
Sung, Korea). The mice were provided with water and food, 
ad libitum and quarantined under 12 h light: 12 h dark photo-
period in the animal care facility of the Samsung Biomedical 
Research  Institute,  Samsung  Medical  Center,  Seoul,  Korea. 
Animal care was performed following the ILAR guideline. The 
mice were acclimated for at least one week before any ex-
periments  were  conducted.
Reagents
EY-6 was synthesized and supplied by Dr. Chung-Kyu Ryu 
(Ewha  Women’s  University,  Seoul,  Korea).  RPMI-1640  me-
dium,  fetal  bovine  serum  and  penicillin-streptomycin  were 
obtained from GIBCO laboratories (Grand Island, NY, USA). 
Following  antibodies  for  flow  cytometric  phenotyping  were 
purchased  from  eBioscience  (SanDiego,  CA,  USA);  fluores-
cein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled mo-
noclonal  Abs  for  FAS,  HSP60,  HSP90,  HSP70,  MHC  class  I 
(H2k
b) ,  C D 8 a ,  C D 1 1 c ,  C D 8 0 ,  C D 1 1 b  ( M a c 1 ) ,  a n d  G r - 1 .  
Antibody against CRT was obtained from ABCAM (Cambridge, 
UK). ELISA sets for cytokines including TNF-α and IFN-γ 
was  purchased  from  eBioscience  (SanDiego,  CA,  USA).
Cell lines
C57BL/6  syngeneic  MC38,  a  colon  carcinoma  cell  line  was 
purchased  from  American  type  culture  collection  (ATCC) 
(Rockville, MD, USA). OVA-specific T cell hybridomas, B3Z86/ 
90.14 (B3Z, MHC-I) and DOBW (MHC-II), were kindly pro-
vided  by Dr.  Kyungjae  Kim  (Sahm  Yook  University,  Seoul, 
Korea). All the cell lines were maintained in RPMI-1640 me-
dium supplemented with 10% heat-inactivated fetal bovine se-
rum (FBS), 2 mM glutamine, 100 U/ml penicillin, and 100μg/ 
ml streptomycin (complete medium) unless otherwise speci-
fied.
Ex vivo culture of bone marrow derived DC 
Mononuclear cells (MNCs) from bone marrow were obtained 
from  the  tibia  and  femur  of  cervical  dislocated  C57BL/6 
mouse. Viability of red blood cell (RBC) free-MNCs was rou-
tinely over 90% by trypan blue exclusion. Plastic-adhered pu-
rified  monocytes  (1×10
6/ml)  were  incubated  with  GM-CSF 
and IL-4 (1×10
3 units/ml each) at 37
oC for 7 days in humidi-
fied  CO2  incubator.  Harvested  DCs  were  used  in  following 
experiments:  1)  EY-6  treated  tumor  cell  uptake  by  DC,  2) 
analysis of the effects of EY-6 on cultured DC (cytotoxicity, 
phenotype,  antigen-specific  cross  presentation).
MTT assay
The cells were cultured in the presence of EY-6 (25, 50 and 
100μM) for 24 h, 48 h, or 72 h in 96-well plates (1×10
4/well). 
After  incubation  at  37
oC,  modified  3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyl-tetrazolium bromide (MTT solution, 5 mg/ml, 
20μl) was added and incubated for 4 h at 37
oC. At the end 
of  the  incubation,  supernatant  was  removed  and  the  color 
change induced by Dimethyl sulfoxide (DMSO) was determi-
ned at 540 nm with ELISA reader (Molecular Devices, Sunny-
vale,  CA,  USA).
Flow cytometric analysis
Phenotype observation
EY-6 treated MC38 colon cancer cells stained with fluorescein 
isothiocyanate (FITC)-or phycoerythrin (PE)-labeled monoclo-
nal Abs against FAS, HSP60, HSP90, HSP70, and CRT to ana-
lyse the immunogenicity induction. Cultured BM-DC charac-
terization was performed after EY-6 treatment by staining with 
FITC or PE-conjugated mAb against CD11c, CD8a, H2b (MHC 
I), CD11b, Gr-1, CD80 (B7.1). Stained cells were analysed on 
the FACS Calibur (BD Biosciences, SanJose, CA, USA) within 
3  hrs  after  the  staining.
DC uptake of tumor cells
EY-6 treated tumor cell (MC38) was labeled with CRT-FITC 
then co-cultured with CD11c-PE labeled DC for 6 hr. Flow 
cytometric analysis was performed by FACS Calibur (BD Bio-
sciences,  SanJose,  CA,  USA).  FITC  and  PE  double  positive 
cells  were  considered  as  DCs  taken  tumor  cells.Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell
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Figure 1. EY-6 induced tumor-speci-
fic killing. MC38 cell (A) or cultu-
red BM-DC (B) was treated with 
different doses of EY-6 (25, 50 and
100μM) for 48 hr at 37
oC. At the
end of the incubation, supernatants 
were removed and MTT solution 
was added to analyze the cell death.
Asterisks indicate the statistical 
significance at p＜0.05.
OVA-specific cross-presentation assay
MHC class I-restricted presentation assay
Cultured BM-DCs were treated with different concentrations 
of  EY-6  for  overnight  (1×10
5/well).  DCs  were  added  with 
OVA-peptide (257-264, SIINFEKL) (Peptron, Daejeon, Korea) 
for 2 h incubation at 37
oC. After the washing twice with PBS, 
cells were fixed with 100μl/well of ice-cold 1% paraformal-
dehyde for 5 min at room temperature. MHC I-restricted OVA- 
specific B3Z cells were (2×10
5/well) co-cultured with above 
DCs for 4 h at 37
oC. After incubation, lacZ activity was meas-
ured by colorimetric analysis of freeze-thaw lysed cells with 
β-galactosidase substrate, cholorphenol red β-D-galactopyr-
anoside (Calbiochem, Darmstadt, Germany) with ELISA read-
er  (Molecular  Devices,  Sunnyvale,  CA,  USA).
MHC class II-restricted presentation assay
EY-6 treated and OVA peptide (323-339, ISQAVHAAHAEINEAGR) 
(Peptron,  Daejeon,  Korea)-introduced-DCs  were  co-cultured 
with MHC II-restricted DOBW cells (1×10
5/well). After 24 h 
incubation  at  37
oC ,  t h e  p l a t e  w a s  c e n t r i f u g e d  a t  1 , 8 0 0  r p m 
to collect the supernatant. OVA-specific secretion of IL-2 was 
measured  in  the  supernatant  by  ELISA.
Statistical analysis
The  analyzed  values  were  reported  as  the  mean±standard 
error.  Statistical  significance  was  determined  by  two-tailed 
Student’s t-test. All p values ＜0.05 were interpreted to repre-
sent  statistically  significant  differences.
RESULTS
EY-6 induced tumor-specific killing
MTT assay was performed to observe the differential cytotoxic 
effect  of  EY-6  against  the  tumor  cell  and  normal  immune 
cells.  MC38,  a  mouse  colon  cancer  cell  line  was  killed  by 
EY-6 in dose-dependent manner (37.5% vs. 30.1% vs. 21.3% 
of non-treated control viability, for 48 hr exposure to 25, 50 
and 100μM EY-6, respectively) (Fig. 1A). Chemical could in-
duce the MC38 apoptosis even with short time (18 hr) of low-
er dose (15μM) exposure as determined by 26.3% annexin 
V
＋PI
＋ ap op to t ic  M C3 8 c el ls.  H ow e ve r t he  c ul tu re d  n o rm al 
BM-DC viability (136.6% vs. 127.0% vs. 157.6% of non-treat-
ed control viability, for 48 hr exposure to 25, 50 and 100μM 
EY-6, respectively) was not affected or slightly proliferated by 
EY-6  (Fig.  1B).  Following  studies  to  define  the  EY-6  indu-
ced-immunological death were performed with 25μM dose.
EY-6 induced immunological death of MC38 colon 
cancer cells
Surface expression of immunogenicity-inducing mole-
cules on the tumor cells killed by EY-6
To observe the ability of EY-6 inducing immunological death 
of tumor cells, chemical treated tumor cell surface molecule 
expression was analyzed by flow cytometry. Death receptor 
Fas (CD95) expression was increased on the chemical-treated 
tumor cells (28.9% vs. 79.2% for the non-treated control vs. 
EY-6 treated MC38, respectively) (Fig. 2). Also the expression 
of natural adjuvant for immune response, heat shock proteins 
(HSPs),  was  induced  on  the  tumor  cell  surface  (7.5%  vs. 
80.6% for Hsp60; 2.5% vs. 28.4% for Hsp70; 16.1% vs. 40.6% 
for  Hsp90  as  control  vs.  EY-6  treated  MC38,  respectively) 
(Fig. 2). The most significant molecule speaks for the increa-
s e d  i m m u n o g e n i c i t y ,  C R T  e x p r e s s i o n  ( 2 0 . 7 %  v s .  5 0 . 4 %  f o r  
control vs. EY-6 treated MC38, respectively) was induced by 
EY-6 (Fig. 2). Thus chemical-treated tumor cells may be up- 
taken and presented to the immune system by DC, more easi-
ly  than  non-treated  cells.
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Figure 2. Surface expression of im-
munogenicity-inducing molecules on
the tumor cells killed by EY-6. MC38
cells were overnight incubated with
or without EY-6 25μM at 37
oC. 
Then cells were stained with FITC 
or PE-tagged antibodies against sur-
face molecules as was described in 
the “Materials and Methods” section.
Figure 3. Increased DC uptake of EY-6 treated MC38 cells. MC38 cells
were overnight incubated with or without EY-6 25μM at 37
oC, then
stained with CRT-FITC. Cultured-DC was stained with CD11c-PE. Two 
cells were co-incubated for 6 hr at 37
oC before observe the proportion
of tumor cell uptake DCs by measuring CD11c
＋CRT
＋ double positive
cells.
Figure 4. Cytokine secretion from the EY-6 treated MC 38 cells. MC38 
cells were treated with EY-6 25μM at 37
oC. At several incubation
time points, supernatants were obtained to measure the secreted 
cytokines (IFN-γ or TNF-α) by ELISA following manufacturer’s 
protocol. Asterisks indicate the statistical significance at p＜0.05.
Increased DC uptake of EY-6 treated MC38 cells
MC38  cell  surface  expression of  Fas,  Hsps,  and  CRT  mole-
cules, which are known to be responsible for the increased 
immunogenicity  of  dead  cells,  was  significantly  induced  by 
EY-6 (Fig. 2). Then to observe the DC uptake of MC38 cells, 
it was observed that the CRT
＋CD11c
＋ double positive propor-
tion in the co-culture of EY-6 treated MC38 cell and CD11c
＋ 
cultured-DC. EY-6 treatment significantly induced DC uptake 
of MC38 tumor cells (9.4% vs. 22.4% for non-treated control 
vs. ET-6 treated MC38, respectively) (Fig. 3). EY-6 induced 
CRT expression on the MC38 surface and DC uptake of these 
cells  were  proportionally  co-related.
Cytokine secretion from the EY-6 treated MC 38 cells
EY-6  treatment  induced  the  secretion  of  IFN-γ f r o m  t h e  
MC38  cells  (Fig.  4).  Secretion  of  an  inflammatory  cytokine 
TNF-α wa s als o in cr ea se d b ut  t h e ab so lu t e le ve l w as ve ry 
low (78.3±7.2 vs.17.1±2.1 pg/ml at 6 h exposure to 25μM 
EY-6 for IFN-γ vs. TNF-α) (Fig. 4). Data indicating that EY-6 
treatment altered the tumor cell microenvironment favorable 
to  anti-tumor  immune  responses.
Direct effect of EY-6 on the normal, cultured-DC
Effect of EY-6 on the DC maturation
Cultured-DC phenotype was observed by flow cytometry to 
see  if  EY-6  directly  induced  the  cultured  DC  maturation. 
Unlike  the  killing  effect  on  the  MC38  tumor  cells,  cul-
tured-DCs were not killed by EY-6 treatment rather, the cell 
proliferation induced slightly (Fig. 1B). Phenotype analysis of 
DC indicated that the Ey-6 did not induce DC maturation as 
was observed by decreased surface expression of CD80 (53.3 
% to 41.1% after EY-6 treatment), and CD11c (48.8% to 37.1% 
after EY-6 treatment) (Fig. 5). However, myeloid derived sup-
pressor cell (MDSC) proportion was clearly reduced by EY-6 
treatment  (26.1%  to  2.1%  in  EY-6  treated  cells),  suggesting 
the possible role of EY-6 on the myeloid cell differentiation 
(Fig.  5).Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell
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Figure 5. Effect of EY-6 on the DC 
maturation. Cultured BM-DC by the
methods described in the “Materials
and Methods” section, was treated 
with 25μM EY-6 for 18∼24 hr at 
37
oC. At the end of the incubation, 
harvested and stained the cells with 
FITC or PE-tagged antibodies for the
surface molecules to identify DCs. 
Figure 6. Effect of EY-6 on the DC for the OVA-specific cross 
presentation to CD4
＋(MHC II) and CD8
＋(MHC I) T cells. Cultured 
BM-DC was treated with EY-6 25μM for overnight, then introduced 
with OVA before start the co-culture with MHC-restricted and OVA-
specific T cell hybridomas. Details of methods are described in the
“Materials and Methods” section. (A) IL-2 (pg/ml) secretion from the 
MHCII-restricted DOBW cells were measured by ELISA. (B) Color 
change induced by lacZ activity in the MHC I-restricted B3Z cells was
measured. Numbers in Y-axes represent the absorption at OD580 nM.
None of the responses were statistically significant.
Effect of EY-6 on the DC for the OVA-specific cross pre-
sentation to CD4
＋ and CD8
＋ T cells
Cultured-DC  presented  OVA  ant i g e n  t o  t h e  O V A - s p e c i f i c  T  
cell hybridomas either by MHC I-restricted (B3Z, CD8
＋ cell) 
and MHC II-restricted (DOBW, CD4
＋ cell) manner. MHC II- 
restricted OVA-specific IL-2 secretion from the DOBW cell was 
not significantly changed by the co-culture with EY-6 treated 
and OVA-introduced DC (270.4, 277.5±35.3, and 295.6±5.5 
pg/ml with non-treated DC control, EY-6 25μM and 50μM 
treated-DC,  respectively)  (Fig.  6A).  Also  MHC  I  restricted 
OVA-specific B3Z cell response by EY-6 treated DC was not 
significant, neither (Fig. 6B). As whole, EY-6 treatment did 
not alter the cross-presentation ability of DCs for both MHC I 
and  MHC  II-restricted  antigens.
DISCUSSION
EY-6  is  newly  synthesized  indoledione  derivatives  with  ex-
pectation of anti-fungal agent by an author (Dr. Chung-Kyu 
Ryu). Interestingly, in our screening test, tumor-specific kill-
ing  by  EY-6  without  affecting  normal  immune  cell  viability 
was observed. Rather, the proliferation of normal splenocytes 
was increased by EY-6 in dose-dependent manner (data not 
shown). With an expectation for developing anti-tumor agent 
having immune-stimulatory  effect,  the influence of  EY-6 on 
the  MC38  mouse  colon  cancer  cell  line  and  normal  mouse 
myeloid-DC was observed. MC38 colon cancer cell was killed 
by EY-6 in dose-dependent manner (Fig. 1A). It has been re-
ported that some of the chemotherapeutics with certain doses 
induce  the  tumor  cell  apoptosis  with  increased  surface  ex-
pression of CRT. CRT is a cytosolic calcium-binding protein 
and expressed on the apoptotic tumor cell surface by certain 
type of chemotherapeutics such as anthracyclines. Surface ex-
pressed CRT work as an eat-me signal to DCs to induce tu-
mor  antigen-specific  immune  responses  (11-13).  Thus,  this 
phenomenon called chemotherapeutics induced “immunolog-
ical death” of tumor cell. In this study, tumor specific killing 
by chemical EY-6 was tested if it can induce the “immuno-
genic tumor cell death”. EY-6 induced MC38 cell surface ex-
pression of not only CRT but also natural adjuvant Hsp 60s, 
70s and 90s which are considered as immunogenicity-related 
molecules (Fig. 2). The CRT expression and the DC uptake 
of  these  dead  cells  were  proportionally  co-related  (Fig.  3) 
meaning EY-6 can induce immunological death of MC38 tu-
mor cells. Interestingly, EY-6 stimulated MC38 tumor cells to 
produce IFN-γ much more than TNF-α (Fig. 4). In general, 
IFN-γ is known to be produced by T cells or NK cells not 
A BCellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell
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by tumor cells. Immunotherapy with IFN-γ secreting tumor 
cells  were  proven  to  be  effective  cancer  vaccine  in  animal 
model  (18,19),  suggesting  that  EY-6-manipulated  IFN-γ s e-
cretion  from  the  MC38  cells  may  be  one  of  the  important 
mechanism for inducing anti-tumor responses. Unlike the an-
ti-tumor immune effect on the tumor cells, EY-6 did not affect 
normal antigen presenting cell, DC maturation or cross pre-
sentation function (Fig. 5 and 6). Together with the fact that 
EY-6 do not kill the normal DC, data confirm the tumor cell 
s p e c i f i c  r e s p o n s e  o f  t h e  c h e m i c a l s .  D a t a  o b s e r v e d  i n  t h i s  
study suggest the possibility of developing EY-6 as a chemo-
therapeutics to kill the tumor cells specifically without toxicity 
to normal cells and manipulate the host immunity favorable 
to  eliminate  the  tumor  cells  by  inducing  immunological 
death.
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